Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 12/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 4/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202165 | 0.80 | HTR2C (0.41) | PER2GAAMAPK1HTR6CRY2 | |
| SCHEMBL19960991 | 0.79 | PER2 (0.44) | PER2CRY2 | |
| SCHEMBL19960981 | 0.74 | HTR2A (0.41) | PER2HTR6HTR2C | |
| SCHEMBL31487330 | 0.72 | KMT2A (0.57) | PER2GAAMAPK1CRY2 | |
| SCHEMBL31486817 | 0.72 | KMT2A (0.57) | PER2GAAMAPK1CRY2 | |
| SCHEMBL31487208 | 0.72 | GAA (0.41) | PER2GAAMAPK1HTR6CRY2 | |
| SCHEMBL31487166 | 0.70 | GAA (0.55) | PER2GAAMAPK1HTR6CRY2 | |
| SCHEMBL31487022 | 0.69 | GAA (0.77) | GAAMAPK1 | |
| SCHEMBL19930265 | 0.69 | HRH1 (0.34) | GAAMAPK1HTR6HTR2C | |
| SCHEMBL31486784 | 0.68 | KMT2A (0.51) | PER2GAAMAPK1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | PER2 4745/4885GAA 2332/4885MAPK1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.